Cargando…

Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer.

Serum aminoglutethimide (AG) and N-acetylaminoglutethimide (NAG) concentrations were measured by high pressure liquid chromatography (HPLC) in 24 postmenopausal women with advanced breast cancer receiving increasing doses of oral AG. Patients received 62.5 mg b.d., 125 mg b.d., 250 mg b.d., and 500...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stuart-Harris, R., Bradbrook, I., Morrison, P., Smith, I. E., Rogers, H. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1985
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977148/ https://www.ncbi.nlm.nih.gov/pubmed/3978028

Ejemplares similares

Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983)

Role of aminoglutethimide in male breast cancer.
por: Harris, A. L., et al.
Publicado: (1986)

A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1985)

Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983)

Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1985)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

Agranulocytosis associated with aminoglutethimide: pharmacological and marrow studies.
por: Harris, A. L., et al.
Publicado: (1986)

Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.
por: Ponder, B. A., et al.
Publicado: (1984)

Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.
por: Williams, C. J., et al.
Publicado: (1993)

Polymorphically acetylated aminoglutethimide in humans.
por: Coombes, R. C., et al.
Publicado: (1982)

Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer.
por: Harris, A. L., et al.
Publicado: (1983)

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
por: MacNeill, F. A., et al.
Publicado: (1992)

Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
por: Coombes, R. C., et al.
Publicado: (1982)

Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.
por: LÃ¸nning, P. E., et al.
Publicado: (1989)

Metabolism of aminoglutethimide in humans: quantification and clinical relevance of induced metabolism.
por: Goss, P. E., et al.
Publicado: (1985)

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
por: MacNeill, F. A., et al.
Publicado: (1994)

The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.
por: Dowsett, M., et al.
Publicado: (1988)

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
por: Pfeiler, G, et al.
Publicado: (2013)

Complexes With Biologically Active Ligands. Part 2. Preparation of Copper(II) Complexes of Positively-Charged Derivatives of Aminoglutethimide
por: Supuran, Claudiu T.
Publicado: (1996)

Synthesis and Characterization of an Inclusion Complex of dl-Aminoglutethimide with β-Cyclodextrin and Its Innovative Application in a Biological System: Computational and Experimental Investigations
por: Ray, Samapika, et al.
Publicado: (2022)

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
por: Frost, Charles E., et al.
Publicado: (2015)

A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
por: Mansi, J. L., et al.
Publicado: (1991)

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
por: Eisen, T, et al.
Publicado: (2000)

Correction to “Synthesis and Characterization of an Inclusion Complex of dl-Aminoglutethimide with β-Cyclodextrin and Its Innovative Application in a Biological System: Computational and Experimental Investigations”
por: Ray, Samapika, et al.
Publicado: (2022)

Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer.
por: Stuart-Harris, R., et al.
Publicado: (1985)

The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
por: Canney, P. A., et al.
Publicado: (1988)

Hydroxyurea pharmacokinetics and precision dosing in low-resource settings
por: Smart, Luke R., et al.
Publicado: (2023)

Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
por: Pegram, Mark D, et al.
Publicado: (2009)

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs
por: Sturkenboom, Marieke G. G., et al.
Publicado: (2021)

Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer
por: Hirabatake, Masaki, et al.
Publicado: (2022)

Prognostic significance of serum prolactin levels in advanced breast cancer.
por: Dowsett, M., et al.
Publicado: (1983)

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
por: Khan, O A, et al.
Publicado: (2011)

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
por: Khan, O A, et al.
Publicado: (2011)

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
por: Chen, Justin A., et al.
Publicado: (2022)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
por: Family, Neiloufar, et al.
Publicado: (2019)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Low dose aspirin blocks breast cancer-induced cognitive impairment in mice
por: Walker, Adam K., et al.
Publicado: (2018)

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis
por: Paccaly, Anne J., et al.
Publicado: (2021)

The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_a1f7u3u8p24vg363cr20v5og9g